A groundbreaking gene therapy, AMT-130, has shown significant success in slowing Huntington's disease progression. Early-stage trials involving 29 patients revealed a 75% reduction in disease progression after 36 months for those receiving a high dose. Delivered via brain surgery, this single-dose treatment offers hope for a disease with no current cure. Researchers hailed the results as 'world-changing', emphasizing the potential to preserve patients' daily function and delay the disease's debilitating effects.

Prepared by Olivia Bennett and reviewed by editorial team.